

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original): The use of oxcarbazepine for the manufacture of a pharmaceutical composition for the improvement of sleep in human patients suffering from chronic pain.

Claim 2. (Original): The use according to claim 1 wherein the pain is diabetic neuropathic pain.

Claim 3. (Currently amended): The use according to claim 1-~~or~~-2 wherein oxcarbazepine is administered at a total dose between about 450 mg/day and about 2100 mg/day.

Claim 4. (Currently amended): The use according to ~~any one of~~ claims 1-~~to~~-3 wherein the sleep is improved by decreasing the frequency of being awakened from sleep due to pain.

Claim 5. (Currently amended): The use according to ~~any one of~~ claims 1-~~to~~-3 wherein the sleep is improved by decreasing the delay of getting to sleep due to pain.

Claim 6. (Currently amended): The use according to ~~any one of~~ claims 1-~~to~~-3 wherein the sleep is improved by feeling rested after sleep.

Claim 7. (Original): A package comprising a pharmaceutical composition comprising as sole active ingredient oxcarbazepine together with instructions for improvement of sleep in human patients suffering from chronic pain.

Claim 8. (Original): A pharmaceutical composition comprising as sole active ingredient oxcarbazepine for the improvement of sleep in human patients suffering from chronic pain.

Claim 9. (Original): A method of improving sleep in human patients suffering from chronic pain, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient at a total dose in the range from about 1500 mg/day to about 2100 mg/day.

Claim 10. (Original): The method of claim 9 wherein a daily dose of from 1650 mg to 1950 mg is administered to the patient.

Claim 11. (Original): The method of claim 10 wherein the daily dose is about 1800 mg.

Claim 12. (Original): A method of improving sleep in human patients suffering from chronic pain, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient at a total dose in the range from about 900 mg/day to about 1500 mg/day.

Claim 13. (Original): The method of claim 12 wherein a daily dose of from 1050 mg to 1350 mg is administered to the patient.

Claim 14. (Original): The method of claim 13 wherein the daily dose is about 1200 mg.

Claim 15. (Original): A method of improving sleep in human patients suffering from chronic pain, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient at a total dose in the range from about 450 mg/day to about 900 mg/day.

Claim 16. (Original): The method of claim 15 wherein a daily dose of from 550 mg to 750 mg is administered to the patient.

Claim 17. (Original): The method of claim 16 wherein the daily dose is about 600 mg.

Claim 18. (Currently amended): The method according to ~~any one of claims 9, 12 or 15~~ wherein oxcarbazepine is administering on a twice daily schedule.

Claim 19. (Currently amended): The method according to ~~any one of claims 1 to 18~~ wherein the patient is suffering from neuropathic pain.

Claim 20. (Currently amended): The method according to ~~any one of claims 1 to 19~~ wherein the patient recruits from the Caucasian population.

Claim 21. (Original): The method of claim 19 wherein oxcarbazepine is administered in the form of a film-coated tablet.

Claim 22. (Original): A method of treating pain in a human patient, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient suffering from pain at a total dose in the range from about 1500 mg/day to about 2100 mg/day.

Claim 23. (Original): The method of claim 22 wherein the daily dose is about 1800 mg.

Claim 24. (Original): A method of treating pain in a human patient, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient suffering from pain at a total dose in the range from about 900 mg/day to about 1500 mg/day.

Claim 25. (Original): The method of claim 24 wherein the daily dose is about 1200 mg.

Claim 26. (Original): A method of treating pain in a human patient, which comprises administering oxcarbazepine or a pharmaceutically acceptable salt thereof to said patient suffering from pain at a total dose in the range from about 450 mg/day to about 900 mg/day.

Claim 27. (Original): The method of claim 26 wherein the daily dose is about 600 mg.

Claim 28. (Currently amended): The method of claim 22, 24 or 26 wherein the patient is suffering from diabetic neuropathic pain.

Claim 29. (Currently amended): The method according to ~~any one of~~ claims 22, 24 or 26 wherein the patient recruits from the Caucasian population.

Claim 30. (Original): The use of oxcarbazepine for the manufacture of a pharmaceutical composition for the treatment of diabetic neuropathic pain.

Claim 31. (Original): A package comprising a pharmaceutical composition comprising as sole active ingredient oxcarbazepine together with instructions for the treatment of pain.